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Abstract
Rationale: New approaches to define factors underlying the immunopathogenesis of pulmonary diseases including
sarcoidosis and tuberculosis are needed to develop new treatments and biomarkers. Comparing the blood transcriptional
response of tuberculosis to other similar pulmonary diseases will advance knowledge of disease pathways and help
distinguish diseases with similar clinical presentations.
Objectives: To determine the factors underlying the immunopathogenesis of the granulomatous diseases, sarcoidosis and
tuberculosis, by comparing the blood transcriptional responses in these and other pulmonary diseases.
Methods: We compared whole blood genome-wide transcriptional profiles in pulmonary sarcoidosis, pulmonary
tuberculosis, to community acquired pneumonia and primary lung cancer and healthy controls, before and after
treatment, and in purified leucocyte populations.
Measurements and Main Results: An Interferon-inducible neutrophil-driven blood transcriptional signature was present in
both sarcoidosis and tuberculosis, with a higher abundance and expression in tuberculosis. Heterogeneity of the sarcoidosis
signature correlated significantly with disease activity. Transcriptional profiles in pneumonia and lung cancer revealed an
over-abundance of inflammatory transcripts. After successful treatment the transcriptional activity in tuberculosis and
pneumonia patients was significantly reduced. However the glucocorticoid-responsive sarcoidosis patients showed a
significant increase in transcriptional activity. 144-blood transcripts were able to distinguish tuberculosis from other lung
diseases and controls.
Conclusions: Tuberculosis and sarcoidosis revealed similar blood transcriptional profiles, dominated by interferon-inducible
transcripts, while pneumonia and lung cancer showed distinct signatures, dominated by inflammatory genes. There were
also significant differences between tuberculosis and sarcoidosis in the degree of their transcriptional activity, the
heterogeneity of their profiles and their transcriptional response to treatment.
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Introduction
Approximately nine million new cases of active tuberculosis
(TB), and 1.4 million deaths from TB, are estimated to occur
globally each year [1]. Prompt diagnosis is vital to avoid treatment
delay, hence the ability to discriminate TB from other pulmonary
conditions which can present similarly to TB, such as sarcoidosis,
or have an acute (community acquired pneumonia) or chronic
(primary lung cancer) presentation is important.
TB and sarcoidosis are widespread multisystem diseases that
preferentially involve the lung and often present in a similar
clinical, radiological and histological manner. Distinguishing these
diseases therefore can require an invasive biopsy. Granuloma
formation is fundamental to both conditions and although the
pathogen Mycobacterium tuberculosis is recognised as the aetiological
cause of TB, what underlies sarcoidosis is unknown [2]. The
pathways involved in granulomatous inflammation are also poorly
understood and there is little understanding of disease-specific
differences. TB and sarcoidosis can also display a similar
presentation to acute pulmonary infectious diseases such as
community acquired pneumonia and chronic lung disorders such
as primary lung cancer.
Given the complexity of these diseases a systems biology
approach may help unravel the principal host immune responses.
Peripheral blood has the capacity to reflect pathological and
immunological changes elsewhere in the body, and identification
of disease associated alterations can be determined by a blood
transcriptional signature [3]. In support of this concept, we
recently demonstrated an interferon (IFN)-inducible blood signa-
ture in patients with pulmonary TB from London and South
Africa [4], which has now been validated in three independent
studies in Africa [5,6] and Indonesia [7]. Blood gene expression
profiling has also been successfully applied to other infectious and
inflammatory disorders, such as systemic lupus erythematosus
(SLE), to help understand disease mechanisms and improve
diagnosis and treatment [3]. Two recent studies have used blood
transcriptional profiling for the comparison of pulmonary TB and
sarcoidosis; both studies found the diseases had similar transcrip-
tional responses, which involved the overexpression of IFN-
inducible genes [8,9]. However these studies did not examine
other similar pulmonary diseases raising the question of whether
these transcriptional signatures also reflected other pulmonary
disorders.
The main objective of our study was to improve our
understanding of the immunopathogenesis underlying sarcoidosis
and TB by comparing the blood transcriptional responses in
pulmonary TB patients to that found in pulmonary sarcoidosis,
pneumonia and lung cancer patients. We also compared the blood
transcriptional responses before and after treatment in each
disease, and examined the transcriptional responses seen in the
different leucocyte populations of the granulomatous diseases.
In addition we investigated the association in sarcoidosis
between clinical activity and the observed blood transcriptional
heterogeneity.
Methods
Study Population and Inclusion Criteria
The majority of the TB patients were recruited from Royal Free
Hospital NHS Foundation Trust, London. The sarcoidosis
patients were recruited from Royal Free Hospital NHS Founda-
tion Trust, St Mary’s Hospital Imperial College NHS Trust,
Barnet and Chase Farm NHS Trust in London, the Oxford
Sarcoidosis Clinic, Churchill Hospital in Oxford, and the
Avicenne Hospital in Paris. The pneumonia patients were
recruited from Royal Free Hospital, London. The lung cancer
patients and 5 of the TB patients in the Test Set were recruited by
the Lyon Collaborative Network, France. All patients were
recruited consecutively over time such that the Training Set was
recruited first followed by the Test Set, Validation Set and lastly
Table 1. Summary of participant numbers in each cohort.
Pulmonary Granulomatous
Diseases Other Pulmonary Diseases TOTAL
TB Sarcoidosis Pneumonia Lung cancer Healthy controls
Training Set 16 25 8 8 38 95
Test Set 11 25 6 8 52 102
Validation Set 8 11 23 42
TOTAL 35 61 14 16 113 239
doi:10.1371/journal.pone.0070630.t001
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the patients’ samples that were used in the cell purification.
Additional blood gene expression data were obtained from
pulmonary and latent TB patients recruited and analysed in our
earlier study which were then re-analysed in this study when
comparing responses before and after TB treatment [10].
The inclusion criteria were specific for each disease. Pulmonary
TB patients: culture confirmed Mycobacterium tuberculosis in either
sputum or bronchoalveolar lavage; pulmonary sarcoidosis: diag-
nosis made by a sarcoidosis specialist, granuloma’s on biopsy,
compatible clinical and radiological findings (within 6 months of
recruitment) according to the WASOG guidelines [11]; commu-
nity acquired pneumonia patients: fulfilled the British Thoracic
Society guidelines for diagnosis [12]; lung cancer patients:
diagnosis by a lung cancer specialist, histological and radiological
features consistent with primary lung cancer; healthy controls:
their gender, ethnicity and age were similar to the patients,
negative QuantiFERON-TB Gold In-Tube (QFT) (Cellestis) test.
The exclusion criteria for all patients and healthy controls included
significant other medical history (including any immunosuppres-
sion such as HIV infection), aged below 18 years or pregnant.
Patients were recruited between September 2009 and March
2012. Patients were recruited before commencing treatment unless
otherwise stated.
Ethics Statement
This study was approved by the Central London 3 Research
Ethics Committee (09/H0716/41) and CPP Sud-Est IV, France,
CCPPRB, Pitie´-salpe´trie`re Hospital, Paris. All participants gave
written informed consent.
IFNc Release Assay Testing
The QFT Assay (Cellestis) was performed according to the
manufacturer’s instructions.
Gene Expression Profiling
3ml of whole blood were collected into Tempus tubes (Applied
Biosystems/Ambion) by standard phlebotomy, vigorously mixed
immediately after collection, and stored between 220 and 280uC
before RNA extraction. RNA was isolated using 1.5ml whole
blood and the MagMAX-96 Blood RNA Isolation Kit (Applied
Biosystems/Ambion) according to the manufacturer’s instructions.
250 mg of isolated total RNA was globin reduced using the
GLOBINclear 96-well format kit (Applied Biosystems/Ambion)
according to the manufacturer’s instructions. Total and globin-
reduced RNA integrity was assessed using an Agilent 2100
Bioanalyzer (Agilent Technologies). RNA yield was assessed using
a NanoDrop8000 spectrophotometer (NanoDrop Products,
Thermo Fisher Scientific). Biotinylated, amplified antisense
complementary RNA (cRNA) targets were then prepared from
200–250ng of the globin-reduced RNA using the Illumina
CustomPrep RNA amplification kit (Applied Biosystems/Am-
bion). 750 ng of labelled cRNA was hybridized overnight to
Illumina Human HT-12 V4 BeadChip arrays (Illumina), which
contained more than 47,000 probes. The arrays were washed,
blocked, stained and scanned on an Illumina iScan, as per
manufacturer’s instructions. GenomeStudio (Illumina) was then
used to perform quality control and generate signal intensity
values.
Cell Purification and RNA Processing for Microarray
Whole blood was collected in sodium heparin. Peripheral blood
mononuclear cells (PBMCs) were separated from the granulo-
cytes/erythrocytes using a LymphoprepTM (Axis-Shield) density
gradient. Monocytes (CD14+), CD4+ T cells (CD4+) and CD8+ T
cells (CD8+) were isolated sequentially from the PBMCs using
magnetic antibody-coupled (MACS) whole blood beads (Miltenyi
Biotec, Germany) according to manufacturer’s instructions.
Neutrophils were isolated from the granulocyte/erythrocyte layer
Figure 1. Pulmonary granulomatous diseases display similar transcriptional signatures that are distinct from pneumonia and lung
cancer. 1446-transcripts were differentially expressed in the whole blood of the Training Set healthy controls, pulmonary TB patients, pulmonary
sarcoidosis patients, pneumonia patients and lung cancer patients. The clustering of the 1446-transcripts were tested in an independent cohort from
which they were not derived from, the Test Set. The heatmap shows the transcripts and Test Set patients’ profiles as organised by the unbiased
algorithm of unsupervised hierarchical clustering. A dotted line is added to the heatmap to help visualisation of the main clusters generated by the
clustering algorithm. Transcript intensity values are normalised to the median of all transcripts. Red transcripts are relatively over-abundant and blue
transcripts under-abundant. The coloured bar at the bottom of the heatmap indicates to which group the profile belongs.
doi:10.1371/journal.pone.0070630.g001
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after red blood cell lysis followed by CD15+ MACS beads
(Miltenyi Biotec, Germany). RNA was extracted from whole blood
(59 Prime PerfectPure Kit) or separated cell populations (Qiagen
RNeasy Mini Kit). Total RNA integrity and yield was assessed as
described above. Biotinylated, amplified antisense complementary
RNA (cRNA) targets were then prepared from 50 ng of total RNA
using the NuGEN WT-OvationTM RNA Amplification and
Encore BiotinIL Module (NuGEN Technologies, Inc). Amplifed
Figure 2. Three dominant clusters of the 1446 differentially expressed transcripts are associated with distinct biological pathways.
Each of the three dominant clusters of transcripts is associated with different study groups in the Training Set. The top transcript cluster is over-
abundant in the pneumonia and cancer patients and significantly associated with IPA pathways relating to inflammation (Fisher’s exact with
Benjamini Hochberg FDR= 0.05). The middle transcript cluster is over-abundant in the TB and sarcoidosis patients and significantly associated with
IFN signalling and other immune response IPA pathways (Fisher’s exact with Benjamini Hochberg FDR= 0.05). The bottom transcript cluster is under-
abundant in all the patients and significantly associated with T and B cell IPA pathways (Fisher’s exact Benjamini Hochberg FDR= 0.05).
doi:10.1371/journal.pone.0070630.g002
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RNA was purified using the Qiagen MinElute PCR purification
kit (Qiagen, Germany). cRNA was then handled as described
above.
Raw Data Processing
Raw data were processed using GeneSpring GX version 11.5
(Agilent Technologies) and the following was applied to all
analyses. After background subtraction each probe was attributed
a flag to denote its signal intensity detection p-value. Flags were
used to filter out probe sets that did not result in a ‘present’ call in
at least 10% of the samples, where the ‘present’ lower cut
off = 0.99. Signal values were then set to a threshold level of 10,
log2 transformed, and per-chip normalised using 75th percentile
shift algorithm. Next per-gene normalisation was applied by
dividing each messenger RNA transcript by the median intensity
of all the samples. All statistical analysis was performed after this
stage. Raw microarray data has been deposited with GEO
(Accession number GSE42834). All data collected and analysed in
Figure 3. Active sarcoidosis signatures are similar to TB but distinct from non-sarcoidosis which resembles healthy controls. 1396-
transcripts are differentially expressed in the whole blood of the Training Set after applying the analysis across six groups to include the two
phenotypes of sarcoidosis patients. (A) The 1396 transcripts and Training Set patients’ profiles are organised by unsupervised hierarchical clustering.
A dotted line is added to the heatmap to clarify the main clusters generated by the clustering algorithm. Transcript intensity values are normalised to
the median of all transcripts. (B) Molecular distance to health of the 1396 transcripts in the Training and Test sets demonstrates the quantification of
transcriptional change relative to the controls. The mean, SEM and p-values are displayed (ANOVA with Tukey’s multiple comparison test).
doi:10.1371/journal.pone.0070630.g003
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Figure 4. Modular analysis shows similar pathways associated with TB and sarcoidosis, differing from pneumonia and cancer. (A)
Gene expression levels of all transcripts that were significantly detected compared to background hybridisation (15212 transcripts, p,0.01) were
compared in the Training Set between each patient group: TB, active sarcoidosis, non-active sarcoidosis, pneumonia, lung cancer, to the healthy
controls. Each module corresponds to a set of co-regulated genes that were assigned biological functions by unbiased literature profiling. A red dot
indicates significant over-abundance of transcripts and a blue dot indicates significant under-abundance (p,0.05). The colour intensity correlates
with the percentage of genes in that module that are significantly differentially expressed. The modular analysis can also be represented in graphical
form as shown in (B)–(E), including both the Training and Test Set samples. The mean, SEM and p-values are displayed (ANOVA with Tukey’s multiple
comparison test). (B) The percentage of genes significantly overexpressed in the 3 IFN modules for each disease. (C) The fold change of the
expression of the genes present in the IFN modules compared to the controls. (D) The percentage of genes significantly overexpressed in the 5
inflammation modules for each disease. (E) The fold change of the expression of the genes present in the inflammation modules compared to the
controls.
doi:10.1371/journal.pone.0070630.g004
Figure 5. Comparison analysis of the diseases compared to matched controls reveals the four most significant pathways.
Differentially expressed genes were derived from the Training Set by comparing each disease to healthy controls matched for ethnicity and gender:
TB = 2524, active sarcoidosis = 1391, pneumonia= 2801 and lung cancer = 1626 transcripts ($1.5 fold change from the mean of the controls, Mann
Whitney with Benjamini Hochberg FDR=0.01). (A) IPA canonical pathways was used to determined the most significant pathways (i-iv) associated
with each disease relative to the other diseases (Fisher’s exact with Benjamini Hochberg FDR= 0.05). The bottom x-axis and bars of each graph
indicates the log (p-value) and the top x-axis and line indicates the percentage of genes present in the pathway. The genes in the EIF2 signalling
pathway are predominately under-abundant genes however the genes in the other three pathways are predominantly over-abundant relative to the
controls. Pathways above the blue dotted line are significant (p,0.05). (B) The IFN signalling IPA pathway is overlaid onto each disease group.
Coloured genes are differentially expressed in that disease group compared to their matched controls (Fisher’s exact FDR= 0.05). Red genes represent
over-abundance and green under-abundance. The pathway for TB is shown enlarged so the detail of the genes can be seen, it is also shown again in
a much smaller scale besides the other diseases so that a visual comparison can be more easily made.
doi:10.1371/journal.pone.0070630.g005
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Figure 6. Unlike TB and pneumonia, successful treatment of sarcoidosis was associated with increased transcriptional activity. (A)
Modular analysis. Gene expression levels of all transcripts that were significantly detected compared to background hybridisation in at least 10% of
samples (p,0.01) were compared between the healthy controls and each of the following the patient groups: pre-treatment pneumonia, post-
treatment pneumonia patients and pre-treatment sarcoidosis, inadequate treatment response sarcoidosis and good-treatment response sarcoidosis
patients. A red dot indicates significant over-abundance of transcripts and a blue dot indicates under-abundance (p,0.05). The colour intensity
correlates to the percentage of genes in that module that are significantly differentially expressed. MDTH demonstrates the quantification of
transcriptional change after treatment in the 1446-transcripts relative to controls. The mean, SEM and p-values are displayed (ANOVA with Tukey’s
multiple comparison test). (B) Pneumonia patients. (D) Sarcoidosis patients. (C) TB patients from the Bloom et al study carried out in South Africa, the
controls in this study were participants with latent TB.
doi:10.1371/journal.pone.0070630.g006
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Figure 7. IFN-inducible gene expression is most abundant in the neutrophils in both TB and sarcoidosis. The expression of IFN-
inducible genes were measured in purified leucocyte populations from whole blood. (A) Heatmap shows the expression of IFN-inducible transcripts,
from the Berry et al 2010 study, for each disease group normalised to the controls for that cell type. (B) The mean expression fold change in the TB
samples of the same IFN-inducible transcripts. (C) The mean expression fold change in the sarcoidosis samples of the same IFN-inducible transcripts.
(D) The mean expression fold change in the TB samples of all the genes present in the three IFN modules compared to the controls. (E) The mean
expression fold change in the sarcoidosis samples of all the genes present in the three IFN modules compared to the controls. Graphs show mean
and SEM.
doi:10.1371/journal.pone.0070630.g007
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Table 2. 144 transcripts.
Symbol FC Exp. Symbol FC Exp. Symbol FC Exp.
C1QB 10.6 UP LOC653610 1.9 UP PLAC8 1.6 UP
LOC100133565 6.4 UP CST7 1.9 UP BAGE5 1.6 UP
TDRD9 5.3 UP LILRB4 1.9 UP DUSP3 1.6 UP
ABCA2 5.3 UP MSL3L1 1.9 UP SLC22A4 1.6 UP
SMARCD3 5.3 UP HIST1H2BG 1.9 UP LOC645159 1.6 UP
CACNA1E 5.1 UP OSM 1.9 UP IL4R 1.6 UP
HP 4.2 UP LILRA5 1.9 UP FLJ32255 1.6 UP
NTN3 4.2 UP GPR97 1.9 UP HIST2H2AA3 1.6 UP
LOC100008589 3.3 UP HIST2H2AC 1.9 UP PLAC8 1.6 UP
CARD17 3.3 UP LILRA5 1.8 UP SH3GLB1 1.6 UP
LOC441763 3.2 UP TLR5 1.8 UP PLSCR1 1.6 UP
ERLIN1 3.1 UP LOC728417 1.8 UP IFI35 1.6 UP
SLPI 3.1 UP MSL3 1.8 UP TAOK1 1.6 UP
SLC26A8 2.9 UP HPSE 1.8 UP MCTP1 1.6 UP
AIM2 2.8 UP RGL4 1.8 UP CEACAM1 1.6 UP
INCA 2.8 UP CYP1B1 1.8 UP B4GALT5 1.6 UP
OPLAH 2.7 UP HIST2H2AA3 1.8 UP COP1 1.6 UP
LPCAT2 2.6 UP AGTRAP 1.8 UP PROK2 1.6 UP
Sep-04 2.5 UP PFKFB3 1.8 UP IFI30 1.6 UP
DISC1 2.5 UP GNG8 1.8 UP FCER1G 1.5 UP
ZFP91 2.5 UP LTB4R 1.8 UP ZNF438 1.5 UP
UBE2J2 2.4 UP H2AFJ 1.8 UP EEF1D 1.5 UP
KREMEN1 2.4 UP LILRA5 1.8 UP MIR21 1.5 UP
ALPL 2.3 UP ABCA1 1.8 UP NGFRAP1 1.5 UP
LOC100008589 2.3 UP SULT1B1 1.8 UP PGS1 1.5 UP
KCNJ15 2.2 UP GYG1 1.7 UP KIF1B 1.5 UP
C19orf59 2.2 UP IFITM1 1.7 UP C16orf57 1.5 UP
FCGR1A 2.2 UP SVIL 1.7 UP ANKRD33 1.5 UP
SPATA13 2.2 UP DGAT2 1.7 UP MXD4 21.5 DOWN
ADM 2.2 UP MEFV 1.7 UP ZSCAN18 21.6 DOWN
CDK5RAP2 2.2 UP PIM3 1.7 UP MEF2D 21.6 DOWN
SNORA73B 2.2 UP MTRF1L 1.7 UP BHLHB2 21.7 DOWN
TncRNA 2.1 UP MAZ 1.7 UP CLC 22.3 DOWN
PPAP2C 2.1 UP HIST2H2AA4 1.7 UP FCER1A 22.5 DOWN
IFITM3 2.1 UP LOC728519 1.7 UP SRGAP3 22.6 DOWN
FCGR1B 2.1 UP SMARCD3 1.7 UP FLJ43093 22.8 DOWN
JMJD6 2.1 UP LOC641710 1.7 UP CCR3 22.9 DOWN
HIST1H3D 2.1 UP HIST2H2BE 1.7 UP EMR4 23 DOWN
LMNB1 2 UP ITPRIPL2 1.7 UP ZNF792 23.1 DOWN
S100A12 2 UP FKBP5 1.7 UP C10orf33 23.5 DOWN
FCGR1C 2 UP IFNAR1 1.6 UP CACNG6 23.8 DOWN
LOC653591 2 UP LY96 1.6 UP P2RY10 24.2 DOWN
LOC100132394 2 UP GPR109A 1.6 UP GATA2 24.6 DOWN
SLC26A8 2 UP DHRS13 1.6 UP EMR4P 26.6 DOWN
ANXA3 2 UP IL18R1 1.6 UP ESPN 27 DOWN
NLRC4 1.9 UP GPR109B 1.6 UP EMR4 29.3 DOWN
LILRA6 1.9 UP AGTRAP 1.6 UP
The 144 transcripts are differentially expressed genes between the TB and active sarcoidosis profiles in the Training Set (significance analysis of microarray q,0.05, fold
change $1.5). FC = Fold change TB versus active sarcoidosis. Exp. = Regulation of expression.
doi:10.1371/journal.pone.0070630.t002
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the experiments adhere to the Minimal Information About a
Microarray Experiment (MIAME) guidelines.
Data Analysis
GeneSpring 11.5 was used to select transcripts that displayed
expression variability from the median of all transcripts (unsuper-
vised analysis). A filter was set to include only transcripts that had
at least twofold changes from the median and present in $10% of
the samples. Unsupervised analysis was used to derive the 3422-
transcripts. Applying a non-parametric statistical filter (Kruskal
Wallis test with a FDR (Benjamini Hochberg) = 0.01), after the
unsupervised analysis, generated the 1446-transcript and 1396-
transcript signatures. The two signatures differed only in which
groups the statistical filter was applied across; 1446, five groups
(TB, sarcoidosis, pneumonia, lung cancer and controls) and 1396,
six groups (TB, active sarcoidosis, non-active sarcoidosis, pneu-
monia, lung cancer and controls).
Differentially expressed genes for each disease were derived by
comparing each disease to a set of controls matched for ethnicity
and gender within a 10% difference. GeneSpring 11.5 was used to
select transcripts that were $1.5 fold different in expression from
the mean of the controls and statistically significant (Mann
Whitney unpaired FDR (Benjamini Hochberg) = 0.01). Compar-
ison Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, Inc.,
Redwood, CA) was used to determine the most significant
canonical pathways associated with the differentially expressed
genes of each disease relative to the other diseases (Fisher’s exact
FDR(Benjamini Hochberg) = 0.05). The bottom x-axis and bars of
each comparison IPA graph indicated the log(p-value) and the top
x-axis and line indicated the percentage of genes present in the
pathway.
Molecular distance to health (MDTH) was determined as
previously described [13], and then applied to different transcrip-
tional signatures. Transcriptional modular analysis was applied as
previously described [14]. The raw expression levels of all
transcripts significantly detected from background hybridisation
were compared between each sample and all the controls present
in that dataset. The percentage of significantly expressed genes in
each module were represented by the colour intensity (Student t-
test, p,0.05), red indicates overexpression and blue indicates
underexpression. The mean percentage of significant genes and
the mean fold change of these genes compared to the controls in
specified modules were also shown in graphical form. MDTH and
modular analysis were calculated in Microsoft Excel 2010.
GraphPad Prism version 5 for Windows was used to generate
the graphs.
Differentially expressed genes between the Training Set TB
patients and active sarcoidosis patients were derived using
Significance Analysis of Microarrays (SAM) (q,0.05) and $1.5
fold expression change [15]. SAM was used due to the increased
sensitivity of this non-parametric test compared to Mann-Whitney
allowing more differentially expressed transcripts to be identified
between TB and active sarcoidosis. Class prediction was
performed within GeneSpring 11.5 using the machine learned
algorithm support vector machines (SVM). The model was built
using sample classifiers ‘TB’ or ‘not TB’. The SVM model should
be built in one study cohort and run in an independent cohort to
prevent over-fitting the predictive signature. This was possible for
all the cohorts from our study. Where the study cohorts used a
different microarray platform the SVM model had to be re-built in
that cohort. To reduce the effects of over-fitting the same SVM
parameters were always used. The kernel type used was linear,
maximum iterations 100,000, cost 100, ratio 1 and validation type
N-fold where N=3 with 10 repeats. The receiver operating curve
(ROC) and area under the curve (AUC) were calculated using
Microsoft Excel 2010.
Univariate and multivariate regression analysis were calculated
using STATA 9 (StataCorp 2005. Stata Statistical Software:
Release 9. College Station, TX; StataCorp LP). In the multivariate
regression analysis where there were missing data points (serum
ACE and HRCT disease activity) to prevent list-wise deletion
dummy variable adjustment was used.
Table 3. Class prediction of 144 transcripts from the Training Set.
Present study Training Set
TB vs non-TB (controls,
sarcoid, cancer, pneumonia)
Present study Test Set
TB vs non-TB (controls, sarcoid,
cancer, pneumonia)
Present study Validation Set
TB vs non-TB (controls &
sarcoid)
Maertzdorf et al
TB vs non-TB (controls
& sarcoid)
Sensitivity 88% 82% 88% 88%
Specificity 94% 91% 92% 97%
Class prediction was performed using support vector machines (SVM). The 144 transcripts derived from the Training Set were used to build the SVM model, the model
was then run in the other two cohorts and the external cohort (Maertzdorf et al).
doi:10.1371/journal.pone.0070630.t003
Table 4. Class prediction of 100 Agilent transcripts from the Maertzdorf et al study.
Present study Training Set
TB vs non-TB (controls,
sarcoid, cancer, pneumonia)
Present study Test Set
TB vs non-TB (controls, sarcoid,
cancer, pneumonia)
Present study Validation





Sensitivity 56% 45% 75% 88% (as stated in their
publication)
Specificity 96% 92% 92% 97% (as stated in their
publication)
Class prediction was performed using support vector machines (SVM). The 100 Agilent transcripts from the Maertzdorf et al study translated to 76 recognised genes
using the DAVID gene converter. The SVM model was built in the Training Set and run in the Test and Validation Sets.
doi:10.1371/journal.pone.0070630.t004
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The power calculations were conducted using the Power
Analysis and Sample Size Software (PASS) 2008.
Results
Blood Transcriptional Profiles are Similar in the
Pulmonary Granulomatous Diseases, TB and Sarcoidosis
but Distinct from Pneumonia and Lung Cancer
Cohorts of TB and sarcoidosis, community acquired pneumonia
and lung cancer patients, and healthy controls are shown in
Table 1 and Figures S1–S3, and appropriately matched demo-
graphically and clinically (Tables S1-2). The study power was
calculated for a training set (standard deviation= 0.4, 3,000 probes
truly differentially expressed, fold change of $1.5, two sample t-
test with FDR of 0.05). Eight to 40 patients per group provide a
power of greater than 0.85 for each probe (calculated using PASS
2008) with minimal benefit of increasing the sample size.
Unbiased analysis demonstrated that the TB and sarcoidosis
blood transcriptional profiles clustered together but distinctly from
pneumonia and cancer, which themselves clustered together
(Training Set; 3422 transcripts, Figure S4A). Statistical filtering
generated 1446 differentially expressed transcripts (Training Set,
Figure S4B). This clustering pattern was verified in an indepen-
dent cohort (Test Set, Figure 1), and was not influenced by
ethnicity or gender (data not shown). Pathway analysis (IPA)
revealed that the TB and sarcoidosis samples were associated with
over-abundance of interferon (IFN) signalling and immune
response pathways (Figure 2). Pneumonia and lung cancer samples
were associated with over-abundance of pathways linked with
inflammation. All diseases showed an under-abundance of T and
B cell pathways.
Heterogeneity of Transcriptional Profiles in Sarcoidosis
Patients Correlates with Clinical Phenotype
Transcriptional profiles of the sarcoidosis patients clustered
either with TB patients or with healthy controls (1446 transcripts,
Figure 1). Patients were thus assessed for disease activity (labelled
as either active or non-active) by a pre-defined decision tree of a
composite of clinical parameters reflecting a snapshot profile of
disease activity at that time-point (Figure S5; Table S3). 1396-
transcripts were found to be differentially expressed using this
sarcoidosis classification. Again active sarcoidosis patients clus-
tered with the TB patients, whereas non-active sarcoidosis patients
clustered with the controls (1396 transcripts, Figure 3A). This was
validated in the independent cohorts Test and Validation Sets
(Figure S6A & B; Table S4A, S4B).
Application of the Molecular distance to health (MDTH)
algorithm [13] to all the disease groups showed that the non-active
sarcoidosis MDTH score was not quantitatively significantly
different from the controls, whereas the active sarcoidosis MDTH
score was (Figure 3B). The TB scores were significantly higher
than the active sarcoidosis scores, and the pneumonia scores were
significantly higher than the lung cancer scores, with pneumonia
and TB having the highest MDTH scores. Collectively, this
suggests a quantitative as well as qualitative difference in blood
transcriptional signatures.
Three Data Mining Strategies Show that TB and Active
Sarcoidosis are Dominated by IFN-inducible Genes,
Whereas Pneumonia and Lung Cancer are Dominated by
Inflammatory Genes
We further investigated the biological pathways associated with
each disease group, using modular analysis, [14], IPA, and
annotation of the top differentially expressed genes for each
disease group. Modular analysis, which takes into account all
genes differentially expressed against controls, verified that TB and
active sarcoidosis showed significant overexpression of the IFN
modules compared to the other pulmonary disease groups
(Figure 4A; Training Set; Figure S7, Test Set), whereas pneumonia
and cancer patients showed significant overexpression of the
inflammation modules (Figure 2). TB patients showed a significant
quantitative increase in the number of IFN-inducible genes and
their degree of expression, compared to the active sarcoidosis
patients (Figures 4B, 4C). Pneumonia and lung cancer showed a
significant increase in the number of genes present in the
inflammation modules and their degree of expression, in
comparison to TB and active sarcoidosis (Figures 4D, 4E).
Pneumonia patients showed an increased number of genes present
in the neutrophil module (Figure S8), correlating with blood
neutrophil count (Spearman’s correlation, r = 0.42, p,0.0001).
Comparison IPA, using genes that were differentially expressed
between each disease group and a matched set of controls,
revealed the most significant pathways when comparing across the
diseases ($1.5 fold change from the controls, Mann Whitney
Benjamini Hochberg p,0.01; TB= 2524, active sarcoido-
sis = 1391, pneumonia = 2801 and lung cancer = 1626 transcripts).
The top four significant pathways were related to protein synthesis
(EIF2 signalling), the immune response, IFN signalling, pattern
recognition receptors recognising bacteria and viruses, and antigen
presentation (Figure 5A and Table S11). Under-abundance of the
EIF2 signalling pathway was driven by the pneumonia patients.
Other genes related to protein synthesis (ribosomal proteins and
other eukaryotic initiation factors) and the unfolded protein
response (a stress response to excessive protein synthesis), were also
significantly under-abundant in the pneumonia patients e.g.
PERK, CHOP, ABCE1 (data not shown). The statistical
significance (bottom x-axis, bar graph, Figure 5A) and percentage
of genes (top x-axis, line graph, Figure 5A) of the three immune
response pathways were driven predominantly by the TB and
active sarcoidosis patients, again demonstrating the similarity of
the biological pathways underlying these diseases. However the
Table 5. Class prediction of 50 genes from the Koth et al study.
Present study Training Set
TB vs non-TB (controls,
sarcoid, cancer, pneumonia)
Present study Test Set
TB vs non-TB (controls,
sarcoid, cancer, pneumonia)
Present study Validation





Sensitivity 75% 45% 50% Not shown in their publication
Specificity 92% 87% 92% Not shown in their publication
Class prediction was performed using support vector machines (SVM). The 50 genes from the Koth et al study were used to build the last SVM model in the Training Set
and run in the Test and Validation Sets.
doi:10.1371/journal.pone.0070630.t005
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IFN-signalling pathway was more significant (Figure 5A) and
contained a higher number of genes in TB than active sarcoidosis
(Figure 5B).
The top 50 over-abundant differentially expressed transcripts
for each disease correlated with the findings from the modular and
IPA analysis where TB and active sarcoidosis were dominated by
IFN-inducible genes e.g. IFITM3, IFIT3, GBP1, GBP6,
CXCL10, OAS1, STAT1, IFI44L, FCGR1B (Table S5). Again
these were greater in number in TB than sarcoidosis. The top 50
over-abundant transcripts in pneumonia were dominated by
antimicrobial neutrophil-related genes e.g ELANE, DEFA1B,
MMP8, CAMP, DEFA3, DEFA4, MPO, LTF. The genes
FCGR1A, B and C were over-abundant in the top 50 transcripts
of all four pulmonary diseases. A 4-set Venn diagram of the
differentially expressed genes demonstrated unique genes for each
disease group (Figure S9 and Table S6), with over three times the
number of unique TB genes than unique active sarcoidosis genes.
The TB unique genes comprised immune responses genes
significantly associated with the IFN-signalling pathway and
antigen presentation. The unique pneumonia genes were associ-
ated with an under-abundance of pathways related to protein
synthesis. The unique lung cancer genes were associated with
over-abundance of inflammation related pathways and under-
abundance of T cell pathways. Overlapping genes common to all
four disease groups were significantly associated with under-
abundance of T and B cell pathways.
TB and Pneumonia Patients after Treatment Showed a
Diminishment of Transcriptional Profiles Whereas
Sarcoidosis Patients Responding to Glucocorticoids
Showed a Significant Increase in Transcriptional Activity
We next examined the transcriptional response to treatment.
Pneumonia patients, followed-up at least 6 weeks after their
hospital discharge, showed a good clinical response to standard
antibiotic treatment (Table S7A) and a diminishment in their
transcriptional profiles to the level of controls by modular analysis
(all detectable transcripts) and MDTH (1446-transcripts)
(Figure 6A & 6B). The MDTH of the 1446-transcripts derived
in the present study of different lung diseases, was also diminished
in the blood of South African TB patients upon completion of
treatment, reverting to the signature of latent TB controls
(Figure 6C) and supporting our previous report [10].
Sarcoidosis patients showed a variable clinical response after
initiation of immunosuppressive treatment as determined by their
practising physician (Table S7B); if their treatment was increased
on clinic follow-up the patient was categorised as having an
‘inadequate treatment response’; continuing the same treatment or
reducing treatment categorised the patient as having a ‘good
treatment response’ (Table S7B). Sarcoidosis patients with a ‘good
treatment response’ showed a significantly increased transcrip-
tional activity in inflammatory transcripts although IFN-inducible
transcripts remained unchanged, which was not seen in sarcoidosis
patients with an ‘inadequate treatment response’ (Figure 6A & 6B).
The top 50 overexpressed inflammatory genes in the ‘good
treatment response’ sarcoidosis patients included anti-inflamma-
tory genes e.g IL1R2, DUSP1, IL18R, C-FOS, IkBa and MAPK1
(Table S8).
IFN-inducible Genes are Most Abundant in Neutrophils in
Both TB and Sarcoidosis
Analysis of purified blood cell populations revealed that
neutrophils displayed the highest abundance of IFN-inducible
genes (Figure 7A, B & D; Tables S9 & 10); and monocytes showed
a higher abundance of IFN-inducible genes than lymphocytes in
sarcoidosis as well as TB patients (Figure 7A-E). The findings in
the TB patients were in keeping with our earlier study [4].
TB Patients Can be Distinguished from the Other
Pulmonary Diseases and Healthy Controls
Comparison of the TB transcriptional profiles to the most
similar group, active sarcoidosis, revealed that 144 transcripts were
differentially expressed, including IFN-inducible genes (Table 2;
Training Set; significance analysis of microarray q,0.05, fold
change $1.5). Using the machine learning algorithm, support
vector machines (SVM), these 144 transcripts showed good
sensitivity (above 80%) and specificity (above 90%), in all three
independent cohorts from our own study (Training, Test and
Validation Sets) and also when tested in an external cohort from
the Maertzdorf et al study [9] (Table 3, Figures S10 & S11a).
However, 76 of 100 transcripts, recognised as genes by NIH
DAVID Gene ID Conversion Tool, proposed by Maertzdorf et al.
to distinguish TB and sarcoidosis, showed a much lower sensitivity
(45–56%), although similar specificity (above 90%), when tested in
our three independent cohorts (Table 4 & Figure S11b). Fifty
genes shown to be differentially expressed in TB and sarcoidosis by
Koth et al. [8] also resulted in lower sensitivity (75–45%), although
similar specificity (above 87%), when tested in our three
independent cohorts (Table 5 & Figure S11c). It is possible class
prediction was affected by the different microarray platforms used
in each study; however, the external validation of our 144
transcripts (Illumina) in the Maertzdorf et al study (Agilent)
provides further evidence for the discriminative accuracy of the
144 transcripts. There were few overlapping transcripts between
our study, the Maertzdorf et al study and the Koth et al study; this
may reflect the lack of validation of the transcript lists derived in
both the Maertzdorf and Koth et al studies (Figure S10).
Discussion
We show an IFN-inducible blood transcriptional signature in
patients with the pulmonary granulomatous diseases, TB and
sarcoidosis, which is distinct from other lung diseases representing
acute and chronic conditions, pneumonia and lung cancer, which
were dominated by an inflammatory signature. Sarcoidosis
transcriptional profiles revealed heterogeneity correlating with
clinical disease activity. The IFN-inducible transcripts appeared to
be dominant in the neutrophils in sarcoidosis as well as TB.
Treated-TB and pneumonia patients showed significant diminish-
ment of their transcriptional activity, however, the treatment-
responsive sarcoidosis patients revealed a significantly more active
transcriptional profile dominated by inflammatory transcripts.
We previously reported an IFN-inducible blood transcriptional
signature in patients with pulmonary TB, which correlated with
extent of radiographic disease, diminished upon treatment [4,10],
and now confirmed in other studies [5,6,7]. Similar blood
transcriptional profiles dominated by IFN-signalling in TB and
sarcoidosis patients, using publicly available data (7) and smaller
patient cohorts [8,9], have since been reported. We now
demonstrate an IFN-inducible blood transcriptional signature in
TB and sarcoidosis patients using larger cohorts of independently
recruited participants and new findings of a distinct signature from
pneumonia and lung cancer. The heterogeneity of sarcoidosis
blood transcriptional profiles was explained by a significant
correlation with the clinical activity phenotype, not reported
previously [8,9,16], but in accordance with the known clinical
heterogeneity of sarcoidosis patients [11,17]. Lockstone et al.,
demonstrated a correlation between expression profiles of lung
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biopsies from sarcoidosis patients, and their clinical classification
as progressive-fibrotic or self-limited after follow-up [18]. Collec-
tively these findings suggest the potential for blood transcriptomic
approaches to provide information before prolonged follow-up of
a patient and allow development of much needed tools to
standardise and aid sarcoidosis management.
In contrast to the IFN-signalling pathways in TB and
sarcoidosis, the transcriptomes in pneumonia and lung cancer
represented inflammation related pathways, in keeping with
different immunopathogenesis of these diseases, and pneumonia
as an infection of the respiratory tract resulting in acute
inflammation of the lungs and peripheral blood [19,20]. The
inflammatory blood transcriptional signature of lung cancer
patients is in keeping with a role for inflammation in primary
lung cancer [21], suggesting blood could be used for further
exploratory studies where tissue is not available. The under-
abundance of transcripts relating to T and B cells in all four
diseases is consistent with previous observations of reduced
numbers of immune cells in the blood of patients with TB,
sarcoidosis and bacterial infection, likely due to migration or death
[4,22,23].
Although TB and sarcoidosis exhibited similar IFN-inducible
transcriptional signatures, the significant quantitative difference in
their transcriptional activity in whole blood and the neutrophils
likely reflects the observed clinical differences. Sarcoidosis patients
with a dominant IFN-inducible signature clustered with the TB
patients whereas those with a much weaker IFN-inducible profile
clustered with the healthy controls. Although IFNc has been
shown to be crucial in controlling mycobacterial infection [24],
type 1 IFN, induced by extracellular mycobacterial DNA
activation of cytosolic receptors [25], or peptidoglycan activation
of the NOD2/IRF5 pathway by [26], may exacerbate TB [27]
[4,10,28]. The immune pathways contributing to sarcoidosis
remain unresolved although suggested to be associated with
macrophage and Th1 activation [29]. It is notable that IFNa
therapy for hepatitis C is a documented risk factor for developing
sarcoidosis (approximately 5% of cases) [30]; and IFNß therapy
has also been associated with case reports of sarcoidosis [31]. That
sarcoidosis and TB patients show a similar transcriptional
signature suggests that the underlying immunological processes
of these two granulomatous diseases have much in common [29].
A frequently suggested aetiological agent for sarcoidosis is
mycobacteria, however the evidence for this is debated [32].
Establishing whether this IFN-inducible signature is reflective of
granulomatous inflammation, or a response to pathogens such as
mycobacteria, requires studies of additional pulmonary granulo-
matous diseases.
Successful treatment of TB and pneumonia patients with anti-
microbial drugs led to diminishment of the blood transcriptional
signature. However, sarcoidosis patients responding successfully to
treatment showed a significant increase in transcriptional activity
by MDTH of inflammatory transcripts, including the anti-
inflammatory genes, IL1R2, IL18RAP, DUSP1, FOS, IkBa and
MAPK1, which invariably accompany the activation of inflam-
matory pathways [33,34,35]. This is consistent with the mixed
transcriptional response found after glucocorticoid stimulation of
blood from healthy donors [36]. However, the IFN-inducible
signature was unchanged. In SLE it has been shown that while
glucocorticoids suppress the inflammatory NF-kB pathway in
many cells, they exerted no effect on secretion of IFNa by
plasmacytoid dendritic cells, providing a potential reason for the
reduced glucocorticoid sensitivity seen in SLE [14]. The under-
lying mechanisms resulting in the partial or negligible clinical
responses towards glucocorticoids seen in many sarcoidosis
patients are as yet undetermined [37].
We identified 144 differentially expressed transcripts between
TB and active sarcoidosis, including IFN-inducible transcripts that
were over-abundant only in the TB patients and distinguished the
TB samples from all other diseases in our three cohorts and an
external cohort (Maertzdorf et al cohort) [9], (sensitivity .80%;
specificity .90%). The two previously published studies compar-
ing whole blood expression profiles of TB and sarcoidosis patients
also derived transcript lists to differentiate the diseases [8,9],
however their lists produced much lower sensitivity, but similar
specificity values when tested against our cohorts. The high
specificity achieved by all transcript lists was due to the very low
Type I error rate attributable to the low prevalence of true TB
samples. Thus blood transcriptional signatures may have promise
as supportive surrogate markers for pulmonary TB diagnosis, after
satisfying rigorous testing and validation in large populations.
We have shown that the blood transcriptome of sarcoidosis like
TB is dominated by an IFN-inducible neutrophil-driven signature,
and heterogeneity of this signature is reflective of disease activity in
sarcoidosis. In contrast, pneumonia and lung cancer were
dominated by an inflammatory signature. Identification of
biological pathways by transcriptomics enhances our understand-
ing of the potential factors underlying pathogens is in the
pulmonary granulomatous diseases TB and sarcoidosis and the
acute and chronic pulmonary diseases, pneumonias and lung
cancers.
Supporting Information
Figure S1 Recruitment flow diagrams for each disease
group and healthy controls in the Training Set.
(PDF)
Figure S2 Recruitment flow diagrams for each disease
group and healthy controls in the Test Set.
(PDF)
Figure S3 Recruitment flow diagrams for each disease
group and healthy controls in the Validation Set.
(PDF)
Figure S4 Pulmonary granulomatous diseases display
similar transcriptional signatures that are distinct from
pneumonia and lung cancer. (A) 3422-transcripts derived by
unsupervised analysis in the Training Set, prior to the application
of a statistical filter, in the whole blood of healthy controls,
pulmonary TB patients, pulmonary sarcoidosis patients, pneumo-
nia patients and lung cancer patients. The 3422 transcripts and
patients’ profiles are organised by unsupervised hierarchical
clustering. (B) After adding a statistical filter to the 3422-
transcripts, 1446-transcripts were derived as differentially ex-
pressed across all the groups in the Training Set. The clustering of
the 1446-transcripts are tested here in an independent cohort, the
Test Set. A dotted line is added to the heatmaps to clarify the main
clusters generated by the clustering algorithm. Transcript intensity
values are normalised to the median of all transcripts. Red
transcripts are relatively over-abundant and blue transcripts
under-abundant. The coloured bar at the bottom of the heatmap
indicates which group the profile belongs to.
(PDF)
Figure S5 Clinical decision tree for classifying sarcoid-
osis patients. The decision tree demonstrates how each
sarcoidosis patient was classified into active pulmonary, active
extra-thoracic or non-active sarcoidosis using clinical variables
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known to be associated with disease activity and routinely
measured as part of standard medical care.
(PDF)
Figure S6 Active sarcoidosis signatures are similar to
TB but distinct from non-sarcoidosis which resembles
healthy controls. 1396-transcripts are differentially expressed in
the whole blood of healthy controls, pulmonary TB patients, active
sarcoidosis patients, non-active sarcoidosis patients, pneumonia
patients and lung cancer patients. The 1396 transcripts and
patients’ profiles are organised by unsupervised hierarchical
clustering. A dotted line is added to the heatmap to clarify the
main clusters generated by the clustering algorithm. Transcript
intensity values are normalised to the median of all transcripts.
Red transcripts are relatively over-abundant and blue transcripts
under-abundant. The coloured bar at the bottom of the heatmap
indicates which group the profile belongs to. (A) Test Set (B)
Validation Set.
(PDF)
Figure S7 Modular analysis shows similar pathways
associated with TB and sarcoidosis, differing from
pneumonia and cancer. Gene expression levels of all
transcripts that were significantly detected compared to back-
ground hybridisation (18894 transcripts, p,0.01) were compared
between each patient group: TB, active sarcoidosis, non-active
sarcoidosis, pneumonia, lung cancer, to the healthy controls in the
Test Set. Each module corresponds to a set of co-regulated genes
that were assigned biological functions by unbiased literature
profiling. A red dot indicates significant over-abundance of
transcripts and a blue dot indicates significant under-abundance
(p,0.05). The colour intensity correlates to the percentage of
genes in that module that are significantly differentially expressed.
(PDF)
Figure S8 Neutrophil module. (A) The mean percentage of
genes significantly overexpressed in the neutrophil module for
each disease in both the Training and Test set. (B) The mean fold
change of the expression of the genes present in the neutrophil
module compared to the controls. The mean, SEM and p-values
are displayed (ANOVA with Tukey’s multiple comparison test).
(PDF)
Figure S9 Venn diagram comparing differentially ex-
pressed genes for each disease group compared to their
matched controls. Differentially expressed genes were derived
from the Training Set by comparing each disease to healthy
controls matched for ethnicity and gender: TB=2524, active
sarcoidosis = 1391, pneumonia= 2801 and lung cancer = 1626
transcripts ($1.5 fold change from the mean of the controls, Mann
Whitney Benjamini Hochberg p,0.01). The 4-set Venn diagram
was created using Venny (Oliveros 2007). IPA canonical pathways
was used to determined the most significant pathways associated
with the unique transcripts for each disease (Fisher’s exact
FDR=0.05). Active Sarc = active sarcoidosis.
(PDF)
Figure S10 Venn diagram comparing the gene lists used
in the class prediction. The gene lists were obtained from this
study (144 Illumina probes), Maertzdorf et al study (100 Agilent
probes of which only 76 probes were recognised as genes using
DAVID converter) and Koth et al study (50 genes obtained from a
Affymetrix platform). In the Illumina platform used to compare
these lists some genes are represented by more than one transcript
for example the 50 genes in Koth et al study translate to 77
Illumina probes/transcripts.
(PDF)
Figure S11 Receiver operating curves of the gene lists
used in the class prediction. Receiver operating curves and
area under the curves calculations are shown in parallel to the
support vector machine results in tables 3–5. (A) 144 transcripts
from our study (B) 76 probes from Maertzdorf et al study (C) 50
genes from Koth et al study.
(PDF)
Table S1 Demographics of the patients and controls
recruited. (A) Training Set and Test Set total numbers, age,
gender and ethnicity. (B) Validation Set.
(PPTX)
Table S2 Clinical characteristics of the Training set are
not significantly different to the Test and Validation
Sets. (A–D) Clinical characteristics of the patients in the Training
Set. (E-H) Comparing the clinical characteristics of the patients in
the Training Set to those of the patients in the Test and Validation
Sets (t-test or Chi-squared p,0.05). BAL=bronchoalveolar
lavage, IGRA= IFN gamma-release assay, Lymph= lymphocyte
count, BHL=bilateral hilar lymphadenopathy, Neut = neutrophil
count, CXR= chest X-ray, ISC= Indian subcontinent, CRP=C-
reactive protein, Ind= indeterminate, ND=not done, N/A=not
available, pred=prednisolone. Dyspnoea = breathlessness. Hae-
moptysis = coughing up blood. CURB65 score = pneumonia
severity score where 5 is the most severe. HT=hypertension.
DM=hypertension. Adeno= adenocarcinoma.
(PPTX)
Table S3 Clinical characteristics and clinical classifi-
cation of sarcoidosis patients as determine by the
decision tree. (A) Training Set (B) Test Set (C) Validation Set
(D) Demographics of all sarcoidosis patients in the three datasets.
CXR= chest radiograph, CT= computer tomography, ACE= an-
giotensin converting enzyme, Lymph= lymphocyte count,
Neut = neutrophil count, TLCO= transfer factor for carbon
monoxide, KCO= transfer coefficient, FVC= forced vital capac-
ity, FEV1= forced expiratory volume in 1 second, Abdo= abdo-
men, LN= lymph node, Med=mediastinal, NA=non-active
sarcoidosis, AET= active extra-thoracic sarcoidosis, Neuro= -
neurological disease.
(PPTX)
Table S4 The clinical classification decision tree used
to categorise patients into either active or non-active
sarcoidosis predicts the clustering of the transcriptional
profiles of the sarcoidosis patients better than standard
single or multiple clinical variables. (A) Univariate
regression analysis to determine which single clinical variables
can best predict those sarcoidosis patients that will cluster with the
TB patients and those that will cluster with the healthy controls as
per the unsupervised clustering of the 1446-transcripts in the
Training set and Test set (see Figures 1 &S4b) (B) Multivariate
analysis to determine the ability of more than one variable to
predict the clustering of the sarcoidosis patients.
(PPTX)
Table S5 The top 50 differentially expressed transcripts
for each disease compared to matched controls. Differ-
entially expressed genes were derived from the Training Set by
comparing each disease to healthy controls matched for ethnicity
and gender: TB= 2524, active sarcoidosis = 1391, pneumo-
nia = 2801 and lung cancer = 1626 transcripts ($1.5 fold change
from the mean of the controls, Mann Whitney Benjamini
Hochberg p,0.01).
(PPTX)
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Table S6 The top 50 differentially expressed transcripts
unique for each disease as determined by the 4-set Venn
diagram. Differentially expressed genes were derived from the
Training Set by comparing each disease to healthy controls
matched for ethnicity and gender ($1.5 fold change from the
mean of the controls, Mann Whitney Benjamini Hochberg
p,0.01). A 4-set Venn diagram was used to identify genes that
were unique for each disease.
(PPTX)
Table S7 Drug therapy given to each sarcoidosis patient
who was commenced on treatment and the clinical
management of their practising physician after observ-
ing their response to the therapy. Each patients study ID
and ‘treatment response category’ correlates with the legend used
for the modular analysis. The superscript number of the
sarcoidosis patients is used when the patient had more than one
visit to their practising physician such that 22 was the visit after
being started on treatment and 23 was the subsequent visit.
(PPTX)
Table S8 Top 50 over-expressed genes in the inflam-
mation modules in the good-treatment response sar-
coidosis patients.
(PPTX)
Table S9 Interferon-inducible genes from the Berry
et al 2010 publication.
(PPTX)
Table S10 Demographics of study participants used in
the cell purification.
(PPTX)
Table S11 List of transcripts present in the IPA
canonical pathways shown in Figure 5. List of all transcripts
by gene symbol that are present in the IPA canonical pathways:
EIF2 signalling, interferon signalling, role of pattern recognition
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